DAFNA Capital Management Return, AUM and Holdings

During the third quarter, DAFNA Capital Management added four positions to its equity portfolio and boosted its investment in some of its previous holdings. The biggest acquisition in this quarter was Spero Therapeutics Inc (NASDAQ:SPRO), whose 70,000 shares with a value of $736,000 the fund obtained. Spero Therapeutics is a clinical-stage biopharmaceutical company located in Cambridge, Massachusetts. The company focuses on developing and commercializing treatments for multi-drug resistant bacterial infections. Another addition was Sutro Biopharma Inc (NASDAQ:STRO) whose 27,494 shares worth $412,000 the fund purchased during the third quarter.

DAFNA Capital Management enhanced its enthusiasm for twenty companies and decided to boost its stakes in those. The biggest increase was in Translate Bio Inc (NASDAQ:TBIO) in which the fund raised its stake by 659% acquiring a total of 151,739 shares worth $1.52 million. The next in line, was Bluebird Bio Inc (NASDAQ:BLUE) in which the fund upgraded its position by 413%, attaining 20,500 shares valued at $2.99 million.

On the opposite side, the fund seems to have lost interest in several companies. It decided to reduce its stakes in a considerable number of them and let go a few others. A significant decrease was made to its position in Minerva Neurosciences Inc (NASDAQ:NERV) in which it lowered its stake by 80% to 26,907 shares valued at $338,000. Also, its stake in Dermira Inc (NASDAQ:DERM) was reduced by 79% to 5,000 shares worth $55,000. DAFNA Capital Management decided to dump its positions in Galmed Pharmaceuticals LTD (NASDAQ:GLMD) where it held 50,000 shares and in Forty Seven Inc (NASDAQ:FTSV) selling the total of its 10,000 shares.

Disclosure: None

This article was originally published on Insider Monkey